Ólafur Pálsson

Ólafur Pálsson has a diverse work experience spanning various industries. Ólafur currently holds the position of Vice President of Global Business Development at PLAIO since May 2022. Prior to this, they worked at ORF Genetics hf./BIOEFFECT, where they held multiple roles, including Chief Sales Officer - North America & UK and International Key Account Director. Their responsibilities at ORF Genetics involved promoting the company's product line BIOEFFECT, which focuses on scientific skincare.

Ólafur also has experience at RISK Medical Solutions, where they served as a Board Member and later as the Managing Director. RISK Medical Solutions is a medical device company that specializes in building individualized algorithms to optimize healthcare systems. Their flagship product focuses on diabetic retinopathy, a leading cause of blindness worldwide.

Additionally, Ólafur worked at Lipid Pharmaceutical as the CFO. Lipid Pharmaceutical was founded in collaboration between Lysi hf. and the Department of Pharmacy at the University of Iceland.

Overall, Ólafur Pálsson's work experience highlights their expertise in business development, sales, key account management, and leadership roles within various industries, including pharmaceuticals, skincare, and medical devices.

Ólafur Pálsson began their education journey in 2005 at Edith Cowan University, where they pursued a Bachelor of Arts (B.A.) degree in Business and international marketing. Ólafur successfully graduated from Edith Cowan University in 2007. Following their undergraduate studies, Ólafur continued their academic pursuits and enrolled at Monash University in 2007 to earn a Master's degree in Financial Risk Management. Ólafur completed their Master's degree program in 2008.